請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78139
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳明汝 | |
dc.contributor.author | Pin-Jhu Wang | en |
dc.contributor.author | 王品筑 | zh_TW |
dc.date.accessioned | 2021-07-11T14:43:30Z | - |
dc.date.available | 2026-08-11 | |
dc.date.copyright | 2016-10-14 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-11 | |
dc.identifier.citation | 白憶欣。2014。潛力益生菌株降低尿毒素硫酸吲哚酚於順鉑誘發急性腎損傷大鼠之研究。國立台灣大學生物資源暨農學院動物科學技術學系。碩士論文。
行政院農業委員會畜產試驗所臺東種畜繁殖場。2010。蘭嶼豬血液生化生理值http://minipigs.angrin.tlri.gov.tw 沈澤臻。2014。藉由小鼠與全隻模式探討Lactobacillus kefiranofaciens M1於異位性皮膚炎之研究。國立臺灣大學生物資源暨農學院動物科學技術學研究所。碩士論文。 洪偉庭。2015。探討Lactobacillus mali 改善腸炎疾病之功效。國立台灣大學生物資源暨農學院動物科學技術學研究所。碩士論文。 謝明瑞。2013。犬貓血漿Indoxyl Sulfate濃度與腎臟疾病相關性之研究。國立中興大學獸醫學系暨研究所。碩士論文。 Alatriste, P. M., R. U. Arronte, C. G. Espinosa, and M. D. L. Cuevas. 2014. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr. Hosp. 29: 582-590. Almaghrabi, O. A. 2015. Molecular and biochemical investigations on the effect of quercetin on oxidative stress induced by cisplatin in rat kidney. Saudi J. Biol. Sci. 22: 227-231. Artis, D. 2008. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat. Rev. Immunol. 8: 411-420. Badary, O. A., M. N. Nagi, H. A. Al-Sawaf, M. Al-Harbi, and A. M. Al-Bekairi. 1997. Effect of L-histidinol on cisplatin nephrotoxicity in the rat. Nephron. 77: 435-439. Badary, O. A., S. Abdel-Maksoud, W. A. Ahmed, and G. H. Owieda. 2005. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci. 76: 2125-2135. Baek, S. M., C. H. Kwon, J. H. Kim, J. S. Woo, J. S. Jung, and Y. K. Kim. 2003. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J. Lab. Clin. Med. 142: 178-186. Barreto, F. C., D. V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, G. Temmar, M. G. Choukroun, R. Vanholder, and Z. A. Massy. 2009. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephro. 4: 1551-1558. Border, W. A., and N. A. Noble. 1997. TGF-β in kidney fibrosis: a target for gene therapy. Kidney Int. 51: 1388-1396. Bratton, S. B., and G. M. Cohen. 2001. Apoptotic death sensor: an organelle’s alter ego? Trends Pharmacol. Sci. 22: 306-315. Chen, Y. P., P. J. Hsiao, W. S. Hong, T. Y. Dai, and M. J. Chen. 2012. Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vivo. J. Dairy Sci. 95: 63-74. Chen, Y. P., T. Y. Lee, W. S. Hong, H. H. Hsieh, and M. J. Chen. 2013. Effects of Lactobacillus kefiranofaciens M1 isolated from kefir grains on enterohemorrhagic Escherichia coli infection using mouse and intestinal cell models. J. Dairy Sci. 96: 7467-7477. Cohen, S. M. and S. J. Lippard. 2001. Cisplatin: From DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67: 93-130. Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 9: 899-909. Corr, S. C., Y. Li, C. U. Riedel, P. W. O'Toole, C. Hill, and C. G. Gahan. 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. 104: 7617-7621. Cruz-Mora, J., N. E. Martínez-Hernández, F. Martín del Campo-López, D. Viramontes-Hörner, B. Vizmanos-Lamotte, J. F. Muñoz-Valle, G. García-García, I. Parra-Rojas, and N. Castro-Alarcón. 2014. Effects of a symbiotic on gut microbiota in mexican patients with endstage renal disease. J. Ren. Nutr. 24: 330-335. Dalmasso, G., F. Cottrez, V. Imbert, P. Lagadec, J. F. Peyron, P. Rampal, D. Czerucka, and H. Groux. 2006. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 131: 1812-1825. Davis, C. A., H. S. Nick, and A. Agarwal. 2001. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J. Am. Soc. Nephrol. 12: 2683-2690. Ebel, B., G. Lemetais, L. Beney, R. Cachon, H. Sokol, P. Langella, and P. Gervais. 2014. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit. Rev. Food Sci. 54: 175-189. Everard, A., C. Belzer, L. Geurts, J. P. Ouwerkerk, C. Druart, L. B. Bindels, Y. Guiot, M. Derrien, G. G. Mucciolid, N. M. Delzenne, and W. M. de Vos. 2013. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. 110: 9066-9071. Fang, C. Y., J. R. Liu, B. J. Chen, C. Wu, Y. P. Chen, and M. J. Chen. 2014. Selection of uremic toxin-reducing probiotics in vitro and in vivo. J. Funct. Foods. 7: 407-415. Fanning, S., L. J. Hall, M. Cronin, A. Zomer, J. MacSharry, D. Goulding, M. O. Motherwaya, F. Shanahana, K. Nallya, G. Dougan, and D. van Sinderen. 2012. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc. Natl. Acad. Sci. 109: 2108-2113. Fayol-Messaoudi, D., C. N. Berger, M. H. Coconnier-Polter, V. Lievin-Le Moal, and A. L. Servin. 2005. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar. Typhimurium. App. Environ. Microb. 71: 6008-6013. Florea, A. M., and D. Büsselberg. 2011. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 3: 1351-1371. Glassock, R. J. 2008. Uremic toxins: what are they? An integrated overview of pathobiology and classification. J. Renal Nutr. 18: 2-6. Guida, B., R. Germanò, R. Trio, D. Russo, B. Memoli, L. Grumetto, F. Barbato, and M. Cataldi. 2014. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr. Metab. Cardiovasc. Dis. 24: 1043-1049. Hanigan, M. H., and P. Devarajan. 2003. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther. 1: 47-61. Hartmann, J. T., C. Kollmannsberger, L. Kanz, and C. Bokemeyer. 1999. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer. 83: 866-869. Hida, M., Y. Aiba, S. Sawamura, N. Suzuki, T. Satoh, and Y. Koga. 1996. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin®, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 74: 349-355. Jo, S. K., W. Y. Cho, S. A. Sung, H. K. Kim, and N. H. Won. 2005. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 67: 458-466. Johnson‐Henry, K. C., K. E. Hagen, M. Gordonpour, T. A. Tompkins, and P. M. Sherman. 2007. Surface‐layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157: H7 adhesion to epithelial cells. Microbiol. 9: 356-367. Jordan, P., and M. Carmo-Fonseca. 2000. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol. Life Sci. 57: 1229-1235. Kadikoylu, G., Z. Bolaman, S. Demir, M. Balkaya, N. Akalin, and Y. Enli. 2004. The effects of desferrioxamine on cisplatin induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum. Exp. Toxicol. 23: 29-34. Kaushal, G. P., V. Kaushal, X. Hong, and S. V. Shah. 2001. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 60: 1726-1736. Kimmel, P. L., T. M. Phillips, S. J. Simmens, R. A. Peterson, K. L. Wiehs, S. Alleyne, I. Cruz, J. A. Yanovski, and J. H. Veis. 1998. Immunologic function and survival in hemodialysis patients. Kidney Int. 54: 236-244. Kintzel, P. E. 2001. Anticancer drug-induced kidney disorders. Drug Safety. 24: 19-38. Ko, W. S., C. H. Guo, M. S. Yeh, L. Y. Lin, G. S. Hsu, P. C. Chen, M. C. Luo, and C. Y. Lin. 2005. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J. Gastroenterol. 11: 4697-4702. Koppe, L., D. mafra, and D. Fouque. 2015. Probiotics and chronic kidney disease. Kidney Int. 88: 958-966. Lopes, P., A. Fuhrmann, J. Sereno, M. J. Pereira, P. Nunes, J. Pedro, A. Melão, F. Reis, and E. Carvalho. 2013. Effects of cyclosporine and sirolimus on insulin-stimulated glucose transport and glucose tolerance in a rat model. Transplant. Proc. 45: 1142-1148. Lyman, J. L. 1986. Blood urea nitrogen and creatinine. Emerg. Med. Clin. North Am. 4: 223-233. Mack, D. R., S. Ahrné, L. Hyde, S. Wei, and M. A. Hollingsworth. 2003. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 52: 827-833. Maxie, M. G. 2016. Jubb, Kennedy, and Palmer’s pathology of domestic animals. 6E. Vol. 2. Elsevier. Medellin-Peña, M. J., H. Wang, R. Johnson, S. Anand, and M. W. Griffiths. 2007. Probiotics affect virulence-related gene expression in Escherichia coli O157: H7. Appl. Environ. Microbiol. 73: 4259-4267. Meyer, T. W., and T. H. Hostetter. 2007. Uremia. N. Engl. J. Med. 357: 1316-1325. Mishra, A., U. S. Chatterjee, and T. K. Mandal. 2013. Induction of chronic renal failure in goats using cisplatin: A new animal model. Toxicol. Int. 20: 56. Nakabayashi, I., M. Nakamura, K. Kawakami, T. Ohta, I. Kato, K. Uchida, and M. Yoshida. 2010. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol. Dial. Transplant. 26: 1094-1098. Nandakumar, D. N., B. C. Koner, R. Vinayagamoorthi, N. Nanda, V. S. Negi, K. Goswami, Z. Bobby, and A. Hamide. 2008. Activation of NF-κB in lymphocytes and increase in serum immunoglobulin in hyperthyroidism: possible role of oxidative stress. Immunobiology. 213: 409-415. Narayanan, S., and H. D. Appleton. 1980. Creatinine: a review. Clin. Chem. 26: 1119-1126. Natarajan, R., B. Pechenyak, U. Vyas, P. Ranganathan, A. Weinberg, P. Liang, M. C. Mallappallil, A. J. Norin, E. A. Friedman, and S. J. Saggi. 2014. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res. Int. 2014: 568571. Niwa, T. 2010a. Uremic toxicity of indoxyl sulfate. Nagoya J. Med. Sci. 72: 1-11. Nossa, C. W., W. E. Oberdorf, L. Yang, J. A. Aas, B. J. Paster, T. Z. DeSantis, E. L. Brodie, D. Malamud, M. A. Poles, and Z. Pei. 2010. Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome. World J. Gastroenterol. 16: 4135-4144. Pabla, N., and Z. Dong. 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73: 994-1007. Patra, A., A. Mandal, S. Roy, S. Mandal, K. C. Mondal, and D. K. Nandi. 2014. Protective effect of selected urease positive Lactobacillus strains on acetaminophen induced uremia in rats. Biomed. Prev. Nutr. 4: 271-276. Pereira, B. J., L. Shapiro, A. J. King, M. E. Falagas, J. A. Strom, and C. A. Dinarello. 1994. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45: 890-896. Polzin, D. J. 2011. Chronic kidney disease in small animals. Vet. Clin. North Am.: Small Animal Practice. 41: 15-30. Prakash, S., and T. M. Chang. 1996. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 2: 883-887. Radin, M. J., M. G. Weiser, and M. J. Fettman. 1986. Hematologic and serum biochemical values for Yucatan miniature swine. Lab. Anim. Sci. 36: 425-427. Ramesh, G., and W. B. Reeves. 2002. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110: 835-842. Ramesh, G., and W. B. Reeves. 2003. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol. Renal Physiol. 285: 610-618. Ranganathan, N., B. G. Patel, P. Ranganathan, J. Marczely, R. Dheer, B. Pechenyak, S. R. Dunn, W. Verstraete, K. Decroos, R. Mehta, and E. A. Friedman. 2006. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J. 52: 70-79. Ranganathan, N., B. Patel, P. Ranganathan, J. Marczely, R. Dheer, T. Chordia, S. R. Dunn, and E. A. Friedman. 2005. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Sci. World J. 5: 652-660. Ranganathan, N., E. A. Friedman, P. Tam, V. Rao, P. Ranganathan, and R. Dheer. 2009. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr. Med. Res. Opin. 258: 1919-1930. Ranganathan, N., P. Ranganathan, E. A. Friedman, A. Joseph, B. Delano, D. S. Goldfarb, P. Tam, A. V. Rao, E. Anteyi, and C. G. Musso. 2010. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv. Ther. 27: 634-647. Rossi, M., D. W. Johnson, M. Morrison, E. Pascoe, J. S. Coombes, J. M. Forbes, B. C. McWhinney, J. P. Ungerer, G. Dimeski, and K. L. Campbell. 2014. SYNbiotics easing renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. Clin. J. Am. Soc. Nephrol. 15: 106. Sadowitz, P. D., B. A. Hubbard, J. C. Dabrowiak, J. Goodisman, K. A. Tacka, M. K. Aktas, M. J. Cunningham, R. L. Dubowy, and A. K. Souid. 2002. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab. Dispos. 30: 183-190. Said, A., C. Desai, and E. V. Lerma. 2015. Chronic kidney disease. Dis. Mon. 61: 374-377. Sánchez-González, P. D., F. J. López-Hernández, J. M. López-Novoa, and A. I. Morales. 2011. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit. Rev. Toxicol. 41: 803-821. Sayin, S. I., A. Wahlström, J. Felin, S. Jäntti, H. U. Marschall, K. Bamberg, B. Angelin, T. Hyötyläinen, M. Orešič, and F. Bäckhed. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17: 225-235. Schumer, M. M., C. A. O’Toole, C. A. Olsson, G. J. Wise, and R. Buttyan. 1992. Morphologic, biochemical and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am. J. Pathol. 140: 831-838. Sheikh-Hamad, D., W. Cacini, A. R. Buckley, J. Isaac, L. D. Truong, C. C. Tsao, and B. K. Kishore. 2004. Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch. Toxicol. 78: 147-155. Shino, Y., Y. Itoh, T. Kubota, T. Yano, T. Sendo, and R. Oishi. 2003. Role of poly (ADP-ribose) polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic. Biol. Med. 35: 966-977. Simenhoff, M. L., S. R. Dunn, G. P. Zollner, M. E. Fitzpatrick, S. M. Emery, W. E. Sandine, and J. W. Ayres. 1996. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner. Electrol. Metab. 22: 92-96. Sleijfer, D. T., S. Meijer, and R. N. H. Mulder. 1985. Cisplatin: a review of clinical applications and renal toxicity. Pharm. Weekbl. 7: 227-237. Somani, S. M., K. Husain, C. Whitworth, G. L. Trammell, M. Malafa, and L. P. Rybak. 2000. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol. Toxicol. 86: 234-241. Somani, S. M., R. Ravi, and L. P. Rybak. 1995. Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system. Drug Chem. Toxicol. 18: 151-170. Swindle, M. M, A. Makin, A. J. Herron, F. J. Clubb, and K. S. Frazier. 2012. Swine as models in biomedical research and toxicology testing. Vet. Pathol. 49: 344-356. Takayama, F., K. Taki, and T. Niwa. 2003. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am. J. Kidney Dis. 41: 142-145. Taki, K., F. Takayama, and T. Niwa. 2005. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J. Ren. Nutr. 15: 77-80. Thigpen, T., R. Vance, L. Puneky, and T. Khansurt. 1994. Chemotherapy in advanced ovarian carcinoma: current standard of care based on randomized trials. Gynecol. Oncol. 55: 597-607. Tuomola, M., M. Vahva, and H. Kallio. 1996. High-performance liquid chromatography Vanholder determination of skatole and indole levels in pig serum, subcutaneous fat, and submaxillary salivary glands. J. Agr. Food Chem. 44: 1265-1270. Turkseven, S., A. Kruger, C. J. Mingone, P. Kaminski, M. Inaba, L. F. Rodella, S. Ikehara, M. S. Wolin, N. G. Abraham. 2005. Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am. J. Physiol. Heart Circ. Physiol. 289: H701-H707. Vanholder, R., R. De Smet, G. Glorieux, A. Argilés, U. Baurmeister, P. Brunet, W. Clark, G. Cohen, P. P. De Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jörres, H. Dieter Lemke, Z. A. Massy, J. Passlick-Deetjen, M. Rodriguez, B. Stegmayr, P. Stenvinkel, C. Tetta, C. Wanner, and W. Zidek. 2003. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63: 1934-1943. Vaziri, N. D., J. Wong, M. Pahl, Y. M. Piceno, J. Yuan, T. Z. DeSantis, Z. Ni, T. Nguyen, and G. L. Andersen. 2013. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 83: 308-315. Vaziri, N. D., J. Yuan, A. Rahimi, Z. Ni, H. Said, and V. S. Subramanian. 2012. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol. Dial. Transpl. 27: 2686-2693. Viramontes-Hörner, D., F. Márquez-Sandoval, F. Martín-del-Campo, B. Vizmanos-Lamotte, A. Sandoval-Rodríguez, J. Armendáriz-Borunda, H. García-Bejarano, K. Renoirte-López, and G. García-García. 2015. Effect of a Symbiotic Gel (Lactobacillus acidophilus + Bifidobacterium lactis + Inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients. J. Ren. Nutr. 25: 284-291. Vitetta, L., A. W. Linnane, and G. C. Gobe. 2013. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins. 5: 2042-2057. Wang, I. K., Y. Y. Wu, Y. F. Yang, I. W. Ting, C. C. Lin, T. H. Yen, J. H. Chen, C. H. Wang, C. C. Huang, and H. C. Lin. 2015. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef. Microbes. 6: 423-430. Xu, Y., B. W. Osborne, and R. C. Stanton. 2005. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am. J. Physiol. Renal Physiol. 289: F1040-F1047. Yang, B., A. M. El Nahas, G. L. Thomas, J. L. Haylor, P. F. Watson, B. Wagner, and T. S. Johnson. 2001. Caspase-3 and apoptosis in experimental chronic renal scarring. Kidney Int. 60: 1765-1776. Yang, H. C., Y. Zuo, and A. B. Fogo. 2010. Models of chronic kidney disease. Drug Discov. Today Dis. Models. 7: 13-19. Yilmaz, H. R., M. Iraz, S. Sogut, H. Ozyurt, Z. Yildirim, O. Akyol, S. Gergerlioglu. 2004. The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharm. Res. 50: 287-290. Zhan, Y., B. van de Water, Y. Wang, and J. L. Stevens. 1999. The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene. 18: 6502-6512. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78139 | - |
dc.description.abstract | 慢性腎臟病為全球共同關注的健康議題,美國約有2600萬位成年人得到不同程度的慢性腎臟病。流行病學研究指出,糖尿病病患和高血壓病患也是罹患慢性腎臟病的高風險族群。通常慢性腎臟病是緩慢且漸進式地喪失腎臟功能,當腎功能損失程度達到後期腎臟病變時,會伴隨著尿毒症的發生。治療方式為透過血液透析減少累積在體內的尿毒素,然而血液透析無法有效地清除與蛋白質小分子結合的尿毒素像是硫酸吲哚酚(indoxyl sulfate, IS)。累積在體內的硫酸吲哚酚進而影響腎臟之功能,造成慢性腎臟病之惡化,研究指出硫酸吲哚酚與慢性腎臟病病程階段以及死亡率有關聯性。
實驗室先前研究證實了將Lactobacillus plantarum subsp. plantarum、Lb. paracasei subsp. paracasei和Streptococcus salivarius subsp. thermophilus三株菌以等比例方式混合稱之為混菌Pm-1,在體外試驗中,混菌Pm-1對於培養基內硫酸吲哚酚之清除效果比起其他單一菌株更好。以順鉑(cisplatin)誘導急性腎衰竭之大鼠模式中,混菌Pm-1有效地降低了大鼠血液中硫酸吲哚酚含量。 由於目前尚未建立慢性腎臟病豬隻模式,本次實驗目的為建立以cisplatin誘導慢性腎臟病蘭嶼豬模式,探討給予混菌Pm-1於cisplatin誘導慢性腎臟病之影響。試驗設計共分成4組,每組3隻8月齡蘭嶼豬。組別分成控制組,給予一般飼糧;cisplatin誘導組,一般飼糧且以靜脈注射cisplatin;低劑量Pm-1組,給予109 CFU/kg BW Pm-1且以靜脈注射cisplatin;高劑量Pm-1組,給予1010 CFU/kg BW Pm-1且以靜脈注射cisplatin,混菌Pm-1會在cisplatin誘導前先給予90天。 結果顯示,高劑量Pm-1組別其血液中肌酸酐及尿素氮之含量比起cisplatin 誘導組有下降的趨勢。透過蘇木紫─伊紅染色和Masson's trichrome染色,高劑量Pm-1組腎臟組織病灶發生率及腎臟纖維化程度皆低於cisplatin誘導組。腎臟組織使用化學免疫組織染色法偵測凋亡蛋白酶-3之表現量,高劑量Pm-1組凋亡蛋白酶-3面積比起cisplatin誘導組有下降的趨勢。高劑量Pm-1組可以降低蘭嶼豬血液中tumor necrosis factor (TNF)-α和interleukin (IL)-6以及過氧化氫酶之含量。在糞便菌相部分,高劑量Pm-1組比起cisplatin誘導組lactobacilli和bifidobacteria有增加,而Clostridium perfringens則是下降。然而給予Pm-1之組別,其血液中硫酸吲哚酚含量並沒有顯著差異。在腸道菌相部分,由熱圖以及主成分分析圖觀察到給予高劑量Pm-1作為前處理,其腸道菌相組成比起cisplatin誘導組更接近控制組。 綜觀上述,給予高劑量Pm-1於cisplatin誘導慢性腎臟病蘭嶼豬在預防其腎臟受損之能力有很好的效果。 | zh_TW |
dc.description.abstract | Chronic kidney disease (CKD) is a global health issue, approximately 26 million American adults are under CKD status. Epidemiological evidences revealed that the patient with diabetes and high blood pressure accompany with high CKD risk. In general, CKD characterized by a gradual dysfunction of kidney, and then caused uremia syndrome. Hemodialysis (HD) is the most common method used to treat uremia syndrome, however, HD is unable to effectively eliminate protein-bound solutes in the advanced stage of CKD. Thus, the accumulation of protein-bound uremic toxins, including indoxyl sulfate (IS), has been suggested to be related to complications and mortality in HD patients.
Our previous study clearly demonstrated that the combination of three strains, Pm-1 which includes Lactobacillus plantarum subsp. plantarum, Lb. paracasei subsp. paracasei and Streptococcus salivarius subsp. thermophilus, have the better ability to reduce uremic toxin, IS, in MRS broth under in vitro and in rat models. In the present study, we developed a cisplatin-induced CKD model using Lanyu pig and investigated the effects of Pm-1 on preventing CKD using this model. Eight-month-old Lanyu pig were divided into four groups, containing three pigs in each group. Nephrotoxicity was induced by intravenous (i. v.) injection of cisplatin dissolved in normal saline. The groups were divided into Control (normal diet without cisplatin injection), CP (normal diet with cisplatin injection), Low Pm-1+CP (1×109 CFU/kg BW Pm-1 with cisplatin injection) and High Pm-1+CP group (1×1010 CFU/kg BW Pm-1 with cisplatin injection). The results indicated that the pigs fed with high dosage of Pm-1 showed the trend to reduce both creatinine and blood urea nitrogen (BUN) when compared with cisplatin group. The high dosage Pm-1 group also demonstrated the lower incidence of lesions in H&E stain and lower fibrosis area in Masson's trichrome stain. The high dosage Pm-1 group also show the lower cleaved caspase-3 positive area on kidney cell apoptosis compared with cisplatin group accompany with suppression of tumor necrosis factor (TNF)-α and interleukin (IL)-6 production and elevation of catalase activity in plasma. In fecal microbiota, Pm-1 administration group had more lactobacilli and bifidobacteria proportion while less Clostridium perfringens when compared with cisplatin group. High dosage Pm-1 show the similar intestinal microbiota component compare with control group in heatmap and principal component analysis (PCA) of the abundance of intestinal microbiota. According to the above results, administration of high dose Pm-1 as pretreatment could alleviate cisplatin-induced CKD in a porcine model. The impressive impact of pretreatment with Pm-1 on the composition of the gut microbiome in cisplatin-induced CKD Lanyu pig model was evidenced by the differences in relative microbial abundance. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:43:30Z (GMT). No. of bitstreams: 1 ntu-105-R03626015-1.pdf: 5265388 bytes, checksum: 78d48d33b90a2fe5df01178ba4f4c43c (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 誌謝………………………………………………………………………………………i
序言……………………………………………………………………………………..iii 中文摘要………………………………………………………………………………..iv 英文摘要………………………………………………….…………………………….vi 目錄……………………………………………………………………………………viii 圖目錄……………………………………………………………………...………….xii 表目錄………………………………………………………………………………….xv 壹、文獻探討 1 第一節:腎臟病 1 一、腎臟疾病 1 二、慢性腎臟病(chronic kidney disease, CKD) 1 第二節:尿毒症(uremia)與尿毒素(uremic toxin) 3 一、尿毒症 3 二、尿毒素之定義 3 三、尿毒素的分類 3 四、硫酸吲哚酚 3 五、IS之形成 4 六、尿毒素治療方式………………………………………………........…4 第三節:腸道微生物與CKD 7 一、腸道微生物與尿毒素之相關 7 二、腸道微生物生態失衡(dysbiosis)與CKD 7 三、益生菌與CKD 10 第四節:順鉑之腎毒性與氧化壓力 18 貳、材料與方法 19 第一節:潛力益生菌株Pm-1之篩選 19 一、實驗材料 19 (一)試驗菌株 19 二、實驗方法 19 (一)菌株之活化與保存 19 1. 菌株之活化 19 2. 菌株之保存 20 (二)含吲哚之培養基製備 20 (三)菌株降解移除吲哚之能力 20 第二節:混菌Pm-1減緩慢性腎臟病蘭嶼豬腎損傷之功效評估 21 一、實驗材料 21 (一) 試驗菌株 21 (二) 實驗動物 21 二、實驗方法 21 (一) 慢性腎臟病之誘導 21 (二) 慢性腎臟病之評估 23 (三) 試驗分組 24 (四) 血液之收集 26 (五) 血液生化值分析 26 (六) 血漿中IS之分析 26 (七) 攝食量之分析 27 (八) 腎臟重量和體重記錄 27 (九) 腎臟組織切片染色 27 (十) 腎臟免疫組織化學染色 27 第三節:混菌Pm-1減緩慢性腎臟病機制之探討 29 一、血液細胞激素測定 29 二、血漿與腎臟組織抗氧化酵素活性測定 29 (一) 腎臟組織均質上清液抗氧化酵素蛋白質濃度測定 29 (二) 超氧化物歧化酶(superoxide dismutase, SOD)活性測定 31 (三) 過氧化氫酶(catalase, CAT)活性測定 31 (四) 谷胱甘肽過氧化物酶(glutathione peroxidase, GPx)活性測定 32 三、腸道菌相分析 32 (一) 糞便微生物菌相分析 32 (二) 盲腸內容物微生物菌相分析 33 (三) 次世代定序分析………………………………….…………..33 第四節:統計分析 37 參、結果與討論 38 第一節:潛力益生菌株Pm-1清除吲哚之能力 38 第二節:潛力益生菌株Pm-1減緩cisplatin誘導CKD蘭嶼豬之能力 40 一、CKD蘭嶼豬模型之建立 40 二、Pm-1對cisplatin誘導CKD蘭嶼豬採食量變化之影響 42 三、Pm-1對cisplatin誘導CKD蘭嶼豬採食量變化之影響 42 四、Pm-1對cisplatin誘導CKD蘭嶼豬血液中尿素氮變化之影響..45 五、Pm-1對cisplatin誘導CKD蘭嶼豬血液中creatinine變化之影響 47 六、Pm-1對cisplatin誘導CKD蘭嶼豬血液中硫酸吲哚酚含量之影響 49 七、腎臟組織切片之評估 51 八、腎臟組織切片纖維化之評估 58 九、腎臟組織cleaved caspase-3免疫染色評估 61 第三節:Pm-1減緩cisplatin誘導CKD蘭嶼豬可能之機制 64 一、血液中細胞激素含量 64 二、腎臟與血液抗氧化酵素之測定 68 三、腸道菌相與CKD之關聯 74 (一) Pm-1減緩cisplatin誘導CKD蘭嶼豬糞便菌相之比例 74 (二) 腸道菌相分析 76 1. 以heatmap分析腸道菌相豐富度…………………………......76 2. 以PCA分析腸道菌相豐富度……………………...................77 肆、結論 105 參考文獻 106 | |
dc.language.iso | zh-TW | |
dc.title | 藉由蘭嶼豬探討益生菌減緩順鉑誘發慢性腎衰竭之研究 | zh_TW |
dc.title | Effect of Potential Probiotics on Alleviating Chronic Kidney Disease Progression Using Cisplatin-Induced Lanyu Porcine Model | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李雅珍,陳彥伯,鄭謙仁,潘子明 | |
dc.subject.keyword | 慢性腎臟病,益生菌,蘭嶼豬,腸道菌相,硫酸??酚, | zh_TW |
dc.subject.keyword | Chronic kidney disease,Probiotic,Lanyu pig,Intestinal microbiota,Indoxyl sulfate, | en |
dc.relation.page | 121 | |
dc.identifier.doi | 10.6342/NTU201602356 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-11 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
dc.date.embargo-lift | 2026-08-11 | - |
顯示於系所單位: | 動物科學技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-R03626015-1.pdf 目前未授權公開取用 | 5.14 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。